09:54:50 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaOB Match
Targovax är ett läkemedelsbolag. Bolaget specialistkompetens återfinns inom riktad immunterapi som används vid behandling av cancerpatienter. Bolagets verksamhet består av forskning och utveckling och läkemedlen säljs idag under separata varumärken. Ett flertal partnerskap på marknaden har ingåtts för att stärka samarbetet inom utvecklingen av ny immunterapi. Bolaget grundades 2010 och har sitt huvudkontor i Oslo.


2022-02-17 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-08-18 Kvartalsrapport 2021-Q2
2021-05-06 Kvartalsrapport 2021-Q1
2021-03-18 Ordinarie utdelning TRVX 0.00 NOK
2021-03-17 Årsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-07 Kvartalsrapport 2020-Q1
2020-04-30 Ordinarie utdelning TRVX 0.00 NOK
2020-04-29 Årsstämma 2020
2020-03-11 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-09 Kvartalsrapport 2019-Q1
2019-04-10 Ordinarie utdelning TRVX 0.00 NOK
2019-04-09 Årsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-01 Kvartalsrapport 2018-Q3
2018-08-23 Kvartalsrapport 2018-Q2
2018-05-03 Kvartalsrapport 2018-Q1
2018-04-12 Ordinarie utdelning TRVX 0.00 NOK
2018-04-11 Årsstämma 2018
2018-02-15 Bokslutskommuniké 2017
2017-11-16 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-04-25 Kvartalsrapport 2017-Q1
2017-04-05 Årsstämma 2017
2017-02-16 Bokslutskommuniké 2016
2016-11-17 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-12 Kvartalsrapport 2016-Q1
2016-04-14 Ordinarie utdelning TRVX 0.00 NOK
2016-04-13 Årsstämma 2016
2015-06-23 Ordinarie utdelning TRVX 0.00 NOK
2015-06-22 Årsstämma 2015
2021-05-06 07:00:20
Oslo, Norway, 6 May 2021 - Targovax ASA (OSE: TRVX), a clinical stage
biotechnology company developing immune activators to target hard-to-treat solid
tumors, today announces its first quarter 2021 results.

An online presentation by Targovax's management to investors, analysts and the
press will take place at 10:00 CET today (details below).



· Reported continued survival benefit in Targovax's ONCOS-102 trial in
mesothelioma at the 21-month follow-up
· Median Overall Survival (mOS) has still not been met for randomized first
-line patients receiving ONCOS-102 plus chemotherapy
· mOS will be at least 20.5 months for randomized first-line patients
receiving ONCOS-102 plus chemotherapy, compared to mOS of 13.5 months in the
chemotherapy-only control group

· Received Fast-Track designation from the US FDA for ONCOS-102 in malignant
pleural mesothelioma. This opens the potential for expedited development path
and review

· Entered a research collaboration with Papyrus Therapeutics to develop novel
ONCOS viruses with receptor tyrosine kinase (RTK) inhibitor functionality


· Announced Dr Sonia Quaratino as a new member of the Board of Directors

· Obtained US Patent for ONCOS-102 in combination with checkpoint inhibitors

· Maintained TG + chemo patent as granted after opposition in European Patent


Amounts in NOK 1Q 2021 1Q 2020 FY 2020

Total operating 318 624
Total operating -23 010 -29 594 -104 524
Operating -23 010 -29 277 -103 901
Net financial items 513 3 278 -4 503
Income tax 16 76 277
Net profit/loss -22 481 -25 923 -108 126

Basic and diluted          -0.26          -0.36  -1.40
EPS (NOK/share)

Net change in cash -26 854 64 860 51 893
Cash and cash 122 321 70 429 70 429
equivalents start of
Cash and cash 95 468 135 289 122 321
equivalents end of

The interim financial information has not been subject to audit

Øystein Soug, CEO commented: "Targovax is at the beginning of a new and exciting
development phase. Based on impressive ONCOS-102 clinical data, our main
priority going forward is to start a next trial in PD1 refractory melanoma. At
the same time, it is also important that we do it right and discuss our strategy
with the FDA, since the aim of this trial is to support an accelerated approval.
Moreover, based on the strength and breadth of the clinical and immune data, we
believe our technology warrants a broader application. Hence, we envision
several expansion possibilities beyond melanoma in other indications, with other
novel combinations, and for our next generation pipeline products."

We invite to a live webcast today at 10.00 CET. You can join the webcast
here (https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20210506_7). It
will be possible to ask questions during the presentation.

Reporting material
report.pdf (https://mb.cision.com/Public/17093/3341418/a2a381340b762811.pdf)
presentation.pdf (https://mb.cision.com/Public/17093/3341418/bfeffc564c835b82.pd
The quarterly report and presentation are also available at the website
www.targovax.com (https://www.targovax.com/en/financial-reports/).


For further information, please contact:
Øystein Soug, CEO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

IR enquires:
Kim Sutton Golodetz - LHA Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777

About Targovax

Activating the patient's immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax aims to unlock
greater clinical benefits in cancer patients by deploying multifunctional
platforms to target key immune regulators and oncogenic drivers. Targovax's
focus is to "activate the patient's immune system to fight cancer", thus
extending and transforming the lives of cancer patients. Targovax's pipeline
aims at different cancer indications, including melanoma, mesothelioma and
colorectal cancer. The products are designed to harness the patient's own immune
system to fight the cancer, whilst also delivering a favorable safety and
tolerability profile.

Targovax's lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging data in several indications, in monotherapy and in multiple
combination, the next development steps for ONCOS-102 will involve a clinical
trial with registration intent in checkpoint inhibitor refractory melanoma.